Announcements
- Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
- Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
- Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
- Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
- Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
- Wave Life Sciences to Present at Upcoming Investor Conferences
- Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
- Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
More ▼
Key statistics
As of last trade WAVE Life Sciences Ltd (1U5:STU) traded at 5.70, -17.39% below its 52-week high of 6.90, set on Mar 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.40 |
---|---|
High | 5.70 |
Low | 5.40 |
Bid | 5.70 |
Offer | 5.80 |
Previous close | 5.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 122.32m |
Free float | 101.89m |
P/E (TTM) | -- |
Market cap | 765.71m USD |
EPS (TTM) | -0.5152 USD |
Data delayed at least 15 minutes, as of May 17 2024.
More ▼